Resources

Amgen wins Interference Judgment

2/25/2003
Sughrue client Amgen, the world's largest biotechnology company and a specialist in human therapeutics, scored a major victory before the Board of Patent Interferences in February, 2003. The Board sided with Amgen's position in deciding that an opponent's claims were held to be unpatentable. The Board also reaffirmed its position by denying a Request for Reconsideration filed by Amgen's opponent. The Interference and Biotechnology practice groups of Sughrue Mion PLLC, argued the case before the Board for biotechnology giant Amgen